Engflag

Prochor

Quick links to important sections

Prochor

Prochor_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prochor

What is Prochor?

Prochor is a medication that belongs to a class of drugs known as phenothiazines. It is primarily utilized for its antiemetic and antipsychotic properties. The active substance in this medication works by affecting the balance of certain natural chemicals in the brain, particularly dopamine, which plays a role in regulating mood, behavior, and the body's physical responses to stimuli.

Primary Uses

Prochor is commonly used in clinical settings for several distinct purposes:

  • Management of Nausea and Vomiting: It is frequently employed to control severe nausea and vomiting associated with various medical conditions or following surgical procedures.
  • Balance and Vertigo: The medication is used to manage symptoms of vertigo and inner ear disorders, such as Ménière's disease, by helping to stabilize the vestibular system.
  • Mental Health Support: In psychiatry, it may be used for the short-term management of anxiety or as part of a treatment plan for certain chronic mental health conditions.

Mechanism of Action

The medication functions by blocking dopamine receptors in the brain. By inhibiting these receptors in the area of the brain that controls nausea (the chemoreceptor trigger zone), it helps to suppress the urge to vomit. In the context of mental health, this same blocking action helps to reduce overactive dopamine signaling, which can assist in calming the nervous system and stabilizing mood.

General Characteristics

Prochor is typically available in various forms, including tablets and injectable solutions, allowing for flexibility based on the patient's needs and the severity of their symptoms. While it is effective for symptomatic relief, it is generally used as part of a broader therapeutic approach tailored to the underlying cause of the symptoms.

Regulatory References

  1. NIH StatPearls: Propranolol

What side effects are possible with Prochor?

Possible Side Effects and Safety Information

The safety profile of Prochor (Propranolol hydrochloride) is defined by its official regulatory classification of documented adverse reactions, which are grouped by the body systems affected and their expected frequency.

Adverse Reaction Classification

Side effects are categorized based on their frequency in clinical use, as documented in official labeling from authorities such as the FDA and EMA.

Classification Examples of Documented Effects (System-Organ Class)
Common Fatigue, weakness, dizziness, sleep disturbances (including nightmares), bradycardia (slow heart rate), cold extremities, nausea, and diarrhea. (Nervous System, Cardiac, Gastrointestinal, Vascular)
Rare Hallucinations, thrombocytopenia, dry eyes, worsening of heart failure, and bronchospasm. (Psychiatric, Blood, Ocular, Cardiac, Respiratory)

Serious Adverse Reactions and Safety Considerations

Official labeling defines specific serious adverse reactions, including the potential for severe bradycardia, intensification of atrioventricular block, and precipitation of heart failure, particularly in susceptible patients. Severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome, are also documented as potential adverse events.

Safety notes for specific populations are included in the regulatory profile. For instance, the medication may mask the adrenergic warning signs of acute hypoglycemia in diabetic patients. Furthermore, there is a risk of severe symptoms, including myocardial infarction (heart attack), if the medicine is abruptly discontinued, particularly in those with pre-existing heart conditions. Its use is formally contraindicated in conditions like cardiogenic shock and bronchial asthma.

Overdose and Emergency Response

The regulatory documentation for Propranolol hydrochloride formally defines an overdose scenario by the manifestation of severe, acute physiological disturbances. Documented clinical signs include profound bradycardia and hypotension, alongside significant CNS depression presenting as drowsiness, confusion, seizures, and the progression to coma. Severe or life-threatening outcomes officially listed are cardiogenic shock, asystole, and CNS-mediated respiratory depression. Other documented signs include bronchospasm, hyperkalaemia, and severe hypoglycaemia.

The official labeling explicitly mandates that individuals must seek immediate medical attention or contact emergency services immediately upon any suspicion of overexposure or the onset of these manifestations.

Management protocols described in regulatory documents require that the administration of the medicine must be stopped. The official procedure involves general symptomatic and supportive measures, including maintaining a clear airway and conducting continuous monitoring of vital signs, mental status, and blood glucose. Specific pharmacological agents, such as beta-receptor agonists and Glucagon, are documented for managing the severe effects. Furthermore, the label notes a heightened risk of hypoglycaemia in vulnerable groups, including children and elderly patients, who are also noted to be at risk for severe cardiovascular compromise.

Therapeutic Uses of Prochor

What Prochor Treats: Main Uses and Benefits

Prochor is commonly used to help manage symptoms linked to organ-specific functional stress within the heart and circulation. The medication is generally used to address symptoms that create noticeable physiological strain in conditions such as hypertension, cardiac arrhythmias, and angina. It is commonly used to help with the management of recurrent migraine headaches and for easing physical discomfort in cases of essential tremor and heightened physiological tension.

Common Therapeutic Contexts

Prochor is applied across therapeutic domains where additional symptomatic support is needed for symptoms related to heightened physiological activity. This includes long-term management scenarios, acute support contexts for post-myocardial infarction stability, and situational uses. In specialized medical settings, it is also considered relevant for pediatric patients for managing specific heart rhythm disorders or to address infantile hemangioma. This assistance supports general well-being during symptomatic phases.

Quick Fact: Relief for Heightened Physiological Tension Prochor is considered relevant when symptoms that interfere with daily functioning (like rapid heart rate or shaking) occur, and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Propranolol

Eligibility and Restrictions for Use

Who Can and Cannot Use Prochor?

The eligibility for Prochor (Propranolol hydrochloride) is strictly defined by regulatory documents, focusing on core cardiac, respiratory, and metabolic functions.

Absolute Contraindications

Prochor must not be used in patients with certain conditions, including bronchial asthma or a history of bronchospasm, cardiogenic shock, decompensated heart failure, severe bradycardia (slow heart rate), or greater than first-degree heart block (Second- or Third-Degree AV block). Use is also prohibited in patients with known hypersensitivity to the drug or its components.

Conditional and Restricted Use

Certain populations must use Prochor with caution and require monitoring as described in the official label:

  • Organ Impairment: Patients with hepatic (liver) or renal (kidney) impairment may require reduced or adjusted dosing, as the body's ability to clear the drug may be diminished.
  • Metabolic Risk: Patients with diabetes mellitus or those after prolonged fasting are at risk, as Prochor can mask the warning signs of hypoglycemia.
  • Age: Older adults may require careful dose determination due to age-related physiological changes. Standard formulations are not established for general pediatric use.
  • Infants: A specific oral solution formulation is approved for treating infantile hemangioma, but only in infants aged 5 weeks to 5 months.

Pregnancy and Lactation Status

Use during pregnancy is generally considered conditional or not recommended unless necessary, and breastfeeding women should inform their doctor, as the drug passes into breast milk.

What should I know about interactions with other medicines?

Prochor's official interaction profile details how co-administration with other substances can modify its concentration or physiological effects. The most critical restriction is the formal contraindication for co-administration with non-dihydropyridine calcium channel blockers, specifically Verapamil and Diltiazem, due to a heightened risk of severe hypotension and cardiac failure.

Regulatory labeling also contains mandatory timing-based rules; for instance, neither Prochor nor Diltiazem/Verapamil should be given intravenously within 48 hours of discontinuing the other. Furthermore, co-administration with Clonidine requires Prochor to be withdrawn several days before Clonidine withdrawal.

Pharmacokinetic interactions are prevalent, as Prochor is metabolized by CYP2D6, CYP1A2, and CYP2C19 enzymes. Medicines that inhibit these enzymes (e.g., Fluoxetine, Cimetidine) may increase exposure to Prochor. Conversely, enzyme inducers (e.g., Rifampin) decrease plasma levels, which can result in a loss of efficacy.

Pharmacodynamic interactions are documented with agents like Digoxin, where co-administration increases the risk of bradycardia. The regulatory profile also notes that Prochor may mask the physical signs of hypoglycemia in patients taking Insulin or oral antidiabetic drugs. Separately, substances like cigarette smoking are documented to increase Prochor clearance, while alcohol may increase Prochor's blood levels.

Mechanism of Action

Prochor functions as a non-selective beta-adrenergic receptor antagonist.

Its biological targets are the beta1 and beta2 adrenergic receptors, where the drug acts as a competitive inhibitor against endogenous catecholamines such as epinephrine and norepinephrine. In cardiac tissue, Prochor's blockade of the beta1 receptor inhibits the G-protein-mediated signaling cascade that normally elevates intracellular cyclic adenosine monophosphate (cAMP) and subsequently activates protein kinase A (PKA). This molecular pathway leads to a downstream cascade of reduced calcium influx through L-type calcium channels.

System-level physiological consequences include a negative chronotropic effect (reduced heart rate) and a negative inotropic effect (decreased myocardial contractility), collectively decreasing cardiac output. Furthermore, beta1 receptor blockade on juxtaglomerular cells in the kidney reduces renin secretion, modulating the renin-angiotensin-aldosterone system (RAAS). Prochor's beta2 receptor antagonism in vascular and bronchial smooth muscle also contributes to systemic effects.

Dosage and Administration Information

How to Use Prochor: Official Administration Guidelines

This section describes the administration guidelines for Prochor (Propranolol hydrochloride), detailing the routes, dosage patterns, and specific timing constraints.

Administration Scope

Instruction Detail
Route of administration Oral for long-term management (tablets, capsules, solution); Intravenous (IV) for acute, monitored administration in clinical settings.
Dosing schedule Treatment begins with a low initial dose that is subject to gradual titration (increase) over specified intervals (e.g., weekly) to reach the required maintenance dose. Adult maintenance doses vary widely, typically ranging from 120 mg to 240 mg total daily dose for IR tablets in hypertension, or 120 mg to 160 mg once daily for SR/XL capsules. IV doses are restricted to 1 mg to 3 mg, administered at a rate not exceeding 1 mg per minute.
Timing in relation to meals Oral doses must be taken consistently each time, regardless of whether they are taken with or without food. The pediatric oral solution is specifically directed to be administered during or immediately after a feeding.
Special procedural conditions Sustained-release capsules must be swallowed whole to preserve the prolonged drug release profile. If treatment must be discontinued, the dosage must be reduced gradually over a period of several weeks rather than stopped abruptly.
Age-group administration rules Dosing for older adults generally requires starting with the lowest effective dose. Pediatric dosing is often weight-based (mg/kg) and involves a specific titration schedule.

Procedural Summary

Administration protocols involve two delivery methods—oral and intravenous—and involve a precise frequency, whether once daily or in divided doses. This process dictates a necessary period of gradual dose adjustment (titration) and requires consistency in the timing of administration. The use structure is defined by procedural constraints, such as the mandated rate limit for IV injection and the necessary gradual dose reduction upon discontinuation.

Recent Clinical Evidence

Research evidence / Overview of Studies for Prochor

The research into Prochor's cardiovascular applications is based on a comprehensive body of evidence, including many Randomized Controlled Trials (RCTs) and Meta-analyses. These studies were evaluated in research contexts involving systemic or functional imbalance, such as high blood pressure (hypertension) and angina (chest discomfort). For hypertension, studies focused on monitoring physiological strain by examining changes in blood pressure levels over both short and long periods. Measurements related to blood pressure levels were described in many of the synthesized RCTs and systematic reviews.

Prochor was studied for managing irregular heart rhythms (arrhythmias) and was observed in trials that included patients after a heart attack (post-myocardial infarction research setting). These trials tracked outcomes like survival rates and the prevention of new or recurring heart events. The study results reflect the specific conditions under which they were conducted, as many trials on stability predate modern cardiac procedures.

Research exploring Prochor's application beyond the cardiovascular system includes trials for conditions characterized by fluctuating or episodic manifestations, specifically essential tremor and migraine headache prevention. For tremor, studies used RCTs to explore short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort and daily-life functioning. For migraine prevention, research examined how symptoms evolved in the observed populations, tracking episodic or acute changes like the frequency and duration of headaches.

The research base for all conditions includes studies with widely varying follow-up durations. For core cardiovascular conditions, long-term evidence was observed in settings tracking major events. Conversely, research for conditions like essential tremor and migraine prevention focused on short-term or intermediate-term periods. There is limited information for long-term outcomes, and extended effects are not fully established for these non-cardiovascular uses.

Prochor was evaluated in studies including adults and certain defined pediatric patients (specifically for arrhythmia and infantile hemangioma). However, data for certain groups remain insufficient, particularly for those with complex comorbid conditions. Subgroup findings are often uncertain because sample sizes were small in the original trials.

Frequently Asked Questions (FAQ)

Common questions about Prochor (FAQ)

Q: Does this medication make you sleepy or affect your ability to drive?

According to official product information, Prochor may cause side effects like dizziness and somnolence (sleepiness). These potential effects could impair a patient's ability to drive or safely operate complex machinery. If you experience these effects, it is advisable to discuss how they may influence your daily activities with a healthcare provider.

Q: What is this medication approved to treat?

Regulatory documents state that Prochor is indicated for several uses in adults. These include managing neuropathic pain from diabetic peripheral neuropathy, postherpetic neuralgia (nerve pain following shingles), and pain associated with spinal cord injury. It is also approved for treating fibromyalgia and as an add-on therapy for partial-onset seizures.

Q: Can children 2 years old use it?

The official product information indicates that Prochor is approved as an add-on treatment for partial-onset seizures in patients who are 1 month of age and older. For all other approved conditions—such as diabetic pain, postherpetic neuralgia, fibromyalgia, or spinal cord injury pain—the medication is not approved for use in patients under 18 years of age.

How should Prochor be stored and disposed of?

Storage and Disposal of Propranolol Hydrochloride

Official regulatory documents define specific storage and disposal requirements for Propranolol hydrochloride (Prochor) to maintain its stability and ensure safety.

Storage Category Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Avoid excessive heat.
Container & Protection Keep the medicine in its original container, tightly closed, and protect from both light and moisture.
Prohibited Conditions The oral solution must not be frozen.
Child Safety Keep out of the sight and reach of children at all times.

Disposal instructions require that any unused or expired product be handled according to local requirements. This generally means utilizing a drug take-back program or, if one is unavailable, disposing of the medication in the household trash after mixing it with an unappealing substance like dirt or used coffee grounds, and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Prochor found in:

A-Z Index: